Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas

In collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology, the College of American Pathologists offers the first evidence-based guideline that comprehensively addresses molecular testing for the diagnosis of diffuse gliomas in the contemporary era.

THE GUIDELINE ANSWERS:
“What ancillary tests are needed to classify diffuse gliomas in order to sufficiently inform the clinical management of patients?”

3 GOOD PRACTICE STATEMENTS
13 RECOMMENDATIONS

Improve patient care beginning with laboratory testing—Implement the recommendations to ensure:

› optimal diagnosis
› risk stratification
› prognosis